The short version
Found is a membership-plus-medication telehealth provider. As of the August 25, 2026 build, for tirzepatide its lowest 12-month all-in total is $4,686 (month-to-month plan, reported), which places it 28 of 30 ranked telehealth providers. Verification status: reported.
The numbers, plan by plan
- Semaglutide (standard, month-to-month plan): no rankable price. "From $99" compounded GLP-1 treatment plus membership/program options from $49; not a standard recurring all-in price.
- Tirzepatide (standard, injection, month-to-month plan): $359 per month after an introductory $149 per month for the first 1 month. Status: reported, checked August 2, 2026. $149 for the first month is supported by Found's store page; the $359 renewal figure comes from a third-party directory (checked August 2, 2026) and was not found on an authoritative checkout page. Membership from $49 per month is billed separately.
Fees and what the price includes
A membership or program fee of $49 per month is billed on top of the medication, so the advertised medication price is not the monthly total. Shipping is billed separately. The clinician consultation is included. The price does not change with dose.
How this pricing structure plays out over a year
The first 1 month costs $198 all-in; from month 2 the recurring cost is $408 a month, so the advertised $149 covers 4% of the first year's spend and the recurring price covers the rest. The price does not move with dose, which removes the largest hidden cost in this market; a patient at 15 mg pays what a patient at 2.5 mg pays. The $49 membership is billed whether or not medication ships that month, which is the structure to read most carefully before a pause or a dose hold.
Compared with the field
On tirzepatide, Found's lowest twelve-month total of $4,686 is $3,186 above the lowest (Trimi, $1,500) and above the median of $3,090 across 30 ranked providers, placing it 28 of 30. On the value score it scores 58 against 92 for NexLife, the best-scoring provider; the gap comes from cost, transparency, care, verification.
Pharmacy, coverage and cancellation
The provider reports serving all fifty states. Dispensing: 503A (provider-stated; pharmacy not named). Commitment: month-to-month membership. Cancellation: Cancel anytime.
Questions to ask Found before paying
Ask, in writing: Which pharmacy fills the prescription, is it 503A or 503B, and can I see a certificate of analysis for my batch? What is the price from month two, and does it change at renewal? Will my dosing instructions state the concentration of the vial you actually ship, and will you reissue them if it changes? A provider that answers all of these promptly is operating in the open; one that will not name its pharmacy has answered the most important question.
What works
Broad medication menu including brand-name and non-GLP-1 options. Coaching and behavior-change program included. Insurance support for brand medication.
What to weigh against it
Membership is separate from medication, so the advertised price understates the monthly total. Medication pricing pending verification.
Who should choose Found
Patients who want a coaching-heavy program and may qualify for insurance-covered brand medication. A patient with insurance coverage for Zepbound or Wegovy should compare the copay route first; a patient who wants a verified flat all-in price with month-to-month flexibility should compare the best overall provider on our value score; and any patient should ask which pharmacy fills the prescription before paying.
How we verified this
Found's site advertises compounded GLP-1 treatment from $99 plus membership/program options from $49; its tirzepatide store page supports a $149 first-month offer, while the $359 renewal figure rests on a third-party directory. Found says it works with licensed 503A pharmacies without naming them. Verified against the provider's own pages on 2026-08-25 (first-party verification pass).